NOS1 and neurofibromatosis type 1: A detailed pharmacological screening of NOS-specific inhibitors, with an emphasis on those that have been tested in humans [94], will shed light on more specific mechanisms and could unveil therapeutic tools for clinical use in NF1 neuropathology.